Neil Buckley active positions
Companies | Position | Start | End |
---|---|---|---|
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Chief Operating Officer | - | - |
Career history of Neil Buckley
Statistics
International
United States | 2 |
Operational
Chief Operating Officer | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Health Technology |
- Stock Market
- Insiders
- Neil Buckley
- Experience